2014 PBAC submissions and outcomes – therapeutic areas
Michael Wonder - January 2015
www.maestrodatabase.com
Submissions
The PBAC considered 170 submissions in 2014 of which 168 were prepared
and lodged by the pharmaceutical industry (sponsors of medicines and medicinal
preparations).
88 (52%) of the 133 submissions were major submissions and 82 (48%) were
minor submissions.
Outcomes
The 170 submissions yielded 244
outcomes. The number of PBAC outcomes
from a given PBAC meeting or analysis period may be greater than the number of
submissions for the same meeting or analysis period as some submissions may
have contained multiple requests and/or multiple patient populations.
Of the 244 outcomes, 157 (64%) were
recommendations, 57 (23%) were rejections and 30 (12%) were deferrals.
Therapeutic
areas
The
therapeutic area with the highest number of outcomes in 2014 was the
antineoplastic and immunomodulatory group with 89 outcomes (53 recommendations
with a success rate of 59%).
The
therapeutic areas with the highest success rates were:
- · Parasitic (2 recommendations and no rejections or deferrals)
- · Systemic hormonal (1 recommendation and no rejections or deferrals)
- · Cardiovascular (20 recommendations and 1 rejection)
©
Wonder Drug Consulting Pty Ltd, 2015.
PBAC 2014 outcomes by therapeutic area
|
Therapeutic area
(WHO ATC main group)
|
Number of
recommendations
|
Number of rejections
|
Number of deferrals
|
Total number of
outcomes
|
Success rate (%)
|
|
Alimentary
|
13
|
7
|
2
|
22
|
59
|
|
Blood
|
3
|
1
|
0
|
4
|
75
|
|
Cardiovascular
|
20
|
1
|
0
|
21
|
95
|
|
Dermatology
|
1
|
1
|
0
|
2
|
50
|
|
Genito-urinary
|
8
|
1
|
0
|
9
|
89
|
|
Systemic hormonal
|
1
|
0
|
0
|
1
|
100
|
|
Anti-infective
|
15
|
7
|
1
|
23
|
65
|
|
Anti-neoplastic and immunomodulatory
|
53
|
17
|
19
|
89
|
59
|
|
Musculoskeletal
|
8
|
1
|
1
|
10
|
80
|
|
Nervous
|
9
|
7
|
0
|
16
|
56
|
|
Parasitic
|
2
|
0
|
0
|
2
|
100
|
|
Respiratory
|
11
|
5
|
0
|
16
|
69
|
|
Sensory
|
7
|
2
|
2
|
11
|
64
|
|
Various
|
14
|
0
|
4
|
18
|
78
|
